Asia-Pacific anticoagulants market is estimated to grow at a CAGR of 7.8% during the forecast period. Researchers from the National Center for CVD in China have examined the prevalence and treatment of increased CVD risk in 1.7 million people from the China PEACE Million Persons Project. It is a Chinese government-funded project being conducted during 2014–2015 across four provinces in the country for CVD screening and management. Of approximately 1.7 million participants with the age group of 35-75 years, 9.5% had an increased risk for CVD. This results in an increasing CVD incidence in the region, which is driving the adoption of anticoagulants in the country.
A full report of Asia-Pacific Anticoagulants Market is available at: https://www.omrglobal.com/industry-reports/asia-pacific-anticoagulants-market
A vitamin K antagonist is utilized for the treatment of thromboembolism with cardiac valve replacement, thromboembolic events post-myocardial infarction, venous thromboembolism, pulmonary embolism, and thromboembolism with atrial fibrillation. In vitamin K antagonist (VKA) anticoagulant, warfarin is the most commonly utilized medication to reduce the risk of stroke in certain atrial fibrillation patients with risk factors. Additionally, NOACs are the ideal suggested drug class compared to warfarin, except for patients suffering from moderate to severe mitral stenosis or an artificial heart valve. NOACs comprises edoxaban, dabigatran, apixaban, and rivaroxaban.
To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/asia-pacific-anticoagulants-market
Scope of the Asia-Pacific Anticoagulants Market
Market Coverage
- Market number available for 2019-2026
- Base year- 2019
- Forecast period- 2020-2026
- Segment Covered- By Type and Application
- Regions Covered- China, India, Japan, and Rest of Asia-Pacific
- Competitive Landscape- Cipla Ltd., Bristol Myers Squibb Co., Pfizer Inc., Daiichi Sankyo Co. Ltd., and Boehringer Ingelheim GmbH
Recent Strategic Initiatives in the Asia-Pacific Anticoagulants Market
- In June 2020, Gland Pharma Ltd. along with its partners Athenex Pharmaceutical Division and MAIA Pharmaceuticals Inc declared the introduction of a ready-to-use Bivalirudin injection in the US. This injection is intended for use as an anticoagulant among patients who are experiencing percutaneous coronary intervention (PCI), which includes patients suffering from heparin-induced thrombocytopenia and thrombosis syndrome, and heparin-induced thrombocytopenia.
- In October 2019, Morepen Labs has added three new drugs, including UDCA (for liver ailments), Rivaroxaban (cardiac segment), and Vildagliptin (diabetes segment) to its active pharmaceutical ingredients (API) portfolio. Rivaroxaban is an anticoagulant which is a blood thinner.
Key questions addressed by the report
- What is the market growth rate?
- Which segment dominates the market in the base year?
- Which segment will project the fastest growth in the market?
- How COVID-19 impacted the market?
o Recovery Timeline
o Deviation from the pre-COVID-19forecast
o Most affected segment
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
Asia-Pacific Anticoagulants Market-Segmentation
By Type
- Novel Oral Anticoagulants (NOACs)
- Vitamin K Antagonist
- Heparin and Low Molecular Weight Heparin (LMWH)
By Application
- Pulmonary Embolism
- Atrial Fibrillation/Myocardial Infarction (Heart Attack)
- Deep Vein Thrombosis (DVT)
- Others
This release has been published on Global Market Post. Global Market Post is not responsible for any content included in this release.
